RxDoctor Payments Data

Holley Ivey, NP

Family · Albany, GANPI 1740630672

Payments from drug & device makers

$2,706in general payments, 2019–2025

Across 117 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$620
  • AstraZeneca$485
  • E.r. Squibb & Sons, L.L.C.$308
  • Novartis$212
  • Amgen$185
  • Merck$171
  • plus $726 from 15 others

What the payments were for

  • Food & beverage$2,706100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,706 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$16,549
Medicare patients
144
Services billed
288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan62$52,463
FarxigaDapagliflozin Propanediol35$29,194
EliquisApixaban38$27,480
JardianceEmpagliflozin11$12,703
XareltoRivaroxaban12$10,398
BrilintaTicagrelor21$8,925
Metoprolol Succinate86$937
Isosorbide Dinitrate18$656
Atorvastatin Calcium84$561
Digoxin17$464
Isosorbide Mononitrate ErIsosorbide Mononitrate44$418
Furosemide78$302
Potassium Chloride11$220
SotalolSotalol Hcl13$173
Carvedilol30$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$212$52,46362 claims
AstraZenecaFarxiga, Brilinta$485$38,12056 claims
PfizerEliquis$65$27,48038 claims
Boehringer IngelheimJardiance$22$12,70311 claims
Johnson & JohnsonXarelto$159$10,39812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →